Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Black, W. Elliott, G. Grandits, P. Grambsch, T. Lucente, W. White, J. Neaton, R. Grimm, L. Hansson, Y. Lacourciére, James Muller, P. Sleight, M. Weber, G. Williams, J. Wittes, A. Zanchetti, R. Anders (2003)
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.JAMA, 289 16
A. Ribeiro, M. Zanella, O. Kohlmann (1999)
Guidelines for treatment of hypertension in Latin America: the Brazilian experience.Clinical and experimental hypertension, 21 5-6
Luz Cubillos-Garzón, J. Casas, C. Morillo, L. Bautista (2004)
Congestive heart failure in Latin America: the next epidemic.American heart journal, 147 3
S. Nissen, E. Tuzcu, P. Libby, P. Thompson, M. Ghali, D. Garza, L. Berman, H. Shi, Ethel Buebendorf, E. Topol, for Investigators (2004)
Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure The CAMELOT Study: A Randomized Controlled TrialJAMA, 292
G. Mancia, Morris Brown, A. Castaigne, P. Leeuw, C. Palmer, T. Rosenthal, G. Wagener, L. Ruilope (2003)
Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)Hypertension: Journal of the American Heart Association, 41
G. Mancia, G. Backer, A. Dominiczak, R. Cífková, R. Fagard, G. Germano, G. Grassi, A. Heagerty, S. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R. Schmieder, H. Boudier, A. Zanchetti (2007)
2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension.Journal of hypertension, 25 9
L. Hansson, T. Hedner, P. Lund-johansen, S. Kjeldsen, L. Lindholm, J. Syvertsen, J. Lanke, U. Faire, B. Dahlöf, B. Karlberg (2000)
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) studyThe Lancet, 356
K. Jamerson, M. Weber, G. Bakris, B. Dahlöf, B. Pitt, V. Shi, A. Hester, Jitendra Gupte, M. Gatlin, E. Velazquez (2008)
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.The New England journal of medicine, 359 23
P. Touboul, R. Hernández-Hernández, S. Küçükoğlu, K. Woo, E. Vicaut, J. Labreuche, C. Migom, H. Silva, R. Vinueza, F. Investigators (2007)
Carotid artery intima media thickness, plaque and framingham cardiovascular score in Asia, Africa/Middle East and Latin America: the PARC-AALA StudyThe International Journal of Cardiovascular Imaging, 23
C. Lawes, S. Hoorn, M. Law, P. Elliott, S. MacMahon, A. Rodgers (2006)
Blood pressure and the global burden of disease 2000. Part II: Estimates of attributable burdenJournal of Hypertension, 24
R. Pastor-Barriuso, J. Banegas, Javier Damin, L. Appel, E. Guallar (2003)
Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Pressure: An Evaluation of Their Joint Effect on MortalityAnnals of Internal Medicine, 139
G.Y. Lip, A.J. Makin (2003)
Treatment of hypertension in peripheral arterial diseaseCochrane Database Syst Rev, 4
G. Burlando, R. Sanchez, F. Ramos, C. Mogensen, A. Zanchetti (2004)
Latin American consensus on diabetes mellitus and hypertension.Journal of hypertension, 22 12
B. Dahlöf, P. Sever, N. Poulter, H. Wedel, D. Beevers, M. Caulfield, R. Collins, S. Kjeldsen, A. Kristinsson, G. Mcinnes, J. Mehlsen, M. Nieminen, E. O’Brien, J. Östergren (2005)
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled triThe Lancet, 366
R. Fuentes, Nina Ilmaniemi, E. Laurikainen, J. Tuomilehto, A. Nissinen (2000)
Hypertension in developing economies: a review of population‐based studies carried out from 1980 to 1998Journal of Hypertension, 18
W. James (2008)
The epidemiology of obesity: the size of the problemJournal of Internal Medicine, 263
V. Dzau, E. Braunwald (1991)
Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement.American heart journal, 121 4 Pt 1
Trefor Morgan, A. Anderson, R. MacInnis (2001)
ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension.American journal of hypertension, 14 3
M. Motro, J. Shemesh (2001)
Calcium Channel Blocker Nifedipine Slows Down Progression of Coronary Calcification in Hypertensive Patients Compared With DiureticsHypertension: Journal of the American Heart Association, 37
Morris Brown, C. Palmer, A. Castaigne, P. Leeuw, G. Mancia, T. Rosenthal, L. Ruilope (2000)
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)The Lancet, 356
S. Baba (2001)
Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics.Diabetes research and clinical practice, 54 3
R. Hernández-Hernández, M. Armas-Padilla, M. Armas-Hernández, M. Velasco (2000)
Hypertension and cardiovascular health in Venezuela and Latin American countriesJournal of Human Hypertension, 14
E. Shinoda, Y. Yui, K. Kodama, A. Hirayama, H. Nonogi, K. Haze, T. Sumiyoshi, S. Hosoda, C. Kawai (2005)
Quantitative Coronary Angiogram Analysis: Nifedipine Retard Versus Angiotensin-Converting Enzyme Inhibitors (JMIC-B Side Arm Study)Hypertension, 45
L. Ghiadoni, A. Magagna, D. Versari, I. Kardasz, Yale Huang, S. Taddei, A. Salvetti (2003)
Different Effect of Antihypertensive Drugs on Conduit Artery Endothelial FunctionHypertension, 41
G. Mancia (2008)
The TALENT StudyEuropean Cardiology Review, 4
P. Ordunez, L. Silva, María Rodríguez, S. Robles (2001)
Prevalence estimates for hypertension in Latin America and the Caribbean: are they useful for surveillance?Revista panamericana de salud publica = Pan American journal of public health, 10 4
D. Yach, C. Hawkes, C. Gould, K. Hofman (2004)
The global burden of chronic diseases: overcoming impediments to prevention and control.JAMA, 291 21
B. Neal, S. MacMahon, N. Chapman (2000)
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trialsThe Lancet, 356
J. Jukema, A. Zwinderman, A. Boven, J. Reiber, A. Laarse, K. Lie, A. Bruschke (1996)
Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group.Arteriosclerosis, thrombosis, and vascular biology, 16 3
C. Dubois, D. Blanchard (1989)
Efficacy and safety of nicardipine in 29,104 patients with hypertension.Clinical therapeutics, 11 4
R. Scognamiglio, R. Nosadini, M. Marin, Stefano Nisti, G. Fasoli, M. Palisi, F. Frigato, F. Virgili, A. Carraro, G. Crepaldi (1997)
Evaluation of the Efficacy and Tolerability of Nitrendipine in Reducing Both Pressure and Left Ventricular Mass in Hypertensive Type 2 Diabetic PatientsDiabetes Care, 20
P. Tatti, M. Pahor, R. Byington, P. Mauro, R. Guarisco, G. Strollo, F. Strollo (1998)
Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDMDiabetes Care, 21
B. Kasiske, Jennie Ma, R. Kalil, T. Louis (1995)
Effects of Antihypertensive Therapy on Serum LipidsAnnals of Internal Medicine, 122
S. Taddei, A. Virdis, L. Ghiadoni, A. Magagna, S. Favilla, A. Pompella, A. Salvetti (2001)
Restoration of Nitric Oxide Availability After Calcium Antagonist Treatment in Essential HypertensionHypertension: Journal of the American Heart Association, 37
T. Gress, F. Nieto, E. Shahar, M. Wofford, F. Brancati (2000)
Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitusThe New England Journal of Medicine, 342
L. Hansson, A. Zanchetti, S. Carruthers, B. Dahlöf, D. Elmfeldt, S. Julius, J. Ménard, K. Rahn, H. Wedel, S. Westerling (1998)
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialThe Lancet, 351
G. Mancia, L. Ruilope, C. Palmer, Morris Brown, A. Castaigne, P. Leeuw, T. Rosental, G. Wagener (2004)
Effects of nifedipine GITS and diuretics in isolated systolic hypertension - a subanalysis of the INSIGHT studyBlood Pressure, 13
S. Lewington, R. Clarke, N. Qizilbash, R. Peto, R. Collins (2002)
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesThe Lancet, 360
B. Neal (2001)
The Blood Pressure Lowering Treatment Trialists' Collaboration
J. Lv, V. Perkovic, C. Foote, M. Craig, J. Craig, G. Strippoli (2012)
Antihypertensive agents for preventing diabetic kidney disease.The Cochrane database of systematic reviews, 12
D. Abegunde, C. Mathers, T. Adam, M. Ortegon, Kathleen Strong (2007)
The burden and costs of chronic diseases in low-income and middle-income countriesThe Lancet, 370
M. Royer, C. Castelo-Branco, J. Blümel, P. Chedraui, L. Danckers, A. Bencosme, D. Navarro, S. Vallejo, M. Espinoza, G. Gómez, H. Izaguirre, F. Ayala, M. Martino, E. Ojeda, W. Onatra, J. Saavedra, K. Tserotas, E. Pozzo, V. Manríquez, M. Prada, E. Grandia, C. Zuñiga, D. Lange, F. Sayegh, for Cl (2007)
The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American womenClimacteric, 10
C. Lawes, S. Hoorn, A. Rodgers (2008)
Global burden of blood-pressure-related disease, 2001The Lancet, 371
H. Schargrodsky, R. Hernández-Hernández, B. Champagne, H. Silva, R. Vinueza, L. Ayçaguer, P. Touboul, C. Boissonnet, J. Escobedo, F. Pellegrini, A. Macchia, E. Wilson (2008)
CARMELA: assessment of cardiovascular risk in seven Latin American cities.The American journal of medicine, 121 1
A. Simon, J. Gariépy, D. Moyse, J. Levenson (2001)
Differential Effects of Nifedipine and Co-Amilozide on the Progression of Early Carotid Wall ChangesCirculation: Journal of the American Heart Association, 103
C. Furberg, J. Wright, B. Davis, J. Cutler, M. Alderman, H. Black, W. Cushman, R. Grimm, L. Haywood, F. Leenen, S. Oparil, J. Probstfield, P. Whelton, C. Nwachuku, D. Gordon, M. Proschan, Paula Einhom, C. Ford, L. Piller, I. Dunn, D. Goff, S. Pressel, Judy Bettencourt, Barbara DeLeon, Lara Simpson, J. Blanton, T. Geraci, Sandra Walsh, C. Nelson, Mahboob Rahman, Anne Juratovac, R. Pospíšil, L. Carroll, Sheila Sullivan, J. Russo, G. Barone, Rudy Christian, S. Feldman, T. Lucente, D. Calhoun, Kimo Jenkins, Peggy McDowell, Janice Johnson, C. Kingry, J. Alzate, K. Margolis, Leslie Holland-Klemme, B. Jaeger, J. Williamson, G. Louis, Pamela Ragusa, A. Williard, R. Ferguson, J. Tanner, J. Eckfeldt, R. Crow, J. Pelosi (2002)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA, 288 23
G. Mancia, G. Grassi, S. Kjeldsen (2008)
2007 ESH–ESC practice guidelines for the management of arterial hypertension
S. Julius, S. Kjeldsen, M. Weber, H. Brunner, S. Ekman, L. Hansson, T. Hua, J. Laragh, G. Mcinnes, Lada Mitchell, F. Plat, A. Schork, Beverly Smith, A. Zanchetti (2004)
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialThe Lancet, 363
M. Ciruzzi, H. Schargrodsky, P. Pramparo, E. Estany, Lidia Naude, Reynaldo Garcia, Samuel Cazarez, E. Meaney, Alecia Nass, B. Finizola, Luis Castillo (2003)
Attributable risks for acute myocardial infarction in four countries of Latin America.Medicina, 63 6
L. Piegas, Á. Avezum, J. Pereira, João Neto, C. Hoepfner, J. Farran, R. Ramos, A. Timerman, J. Esteves (2003)
Risk factors for myocardial infarction in Brazil.American heart journal, 146 2
J. Wright, W. Cushman, B. Davis, J. Barzilay, Pedro Colon, D. Egan, T. Lucente, C. Nwachuku, S. Pressel, F. Leenen, J. Frolkis, R. Letterer, Sandra Walsh, J. Tobin, G. Deger (2001)
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience.Controlled clinical trials, 22 6
J. Chan, G. Ko, D. Leung, Robert Cheung, M. Cheung, W. So, Ramasmyiyer Swaminathan, M. Nicholls, J. Critchley, C. Cockram (2000)
Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.Kidney international, 57 2
A. Rubinstein, L. Alcocer, A. Chagas (2009)
High blood pressure in Latin America: a call to actionTherapeutic Advances in Cardiovascular Disease, 3
F. Lanas, Á. Avezum, L. Bautista, R. Diaz, M. Luna, S. Islam, S. Yusuf (2007)
Risk Factors for Acute Myocardial Infarction in Latin America: The INTERHEART Latin American StudyCirculation, 115
P. Bustos, A. Silva, H. Amigo, H. Bettiol, M. Barbieri (2007)
Metabolic syndrome in young adults from two socioeconomic Latin American settings.Nutrition, metabolism, and cardiovascular diseases : NMCD, 17 8
V. Burt, P. Whelton, E. Roccella, C. Brown, J. Cutler, Millicent Higgins, M. Horan, D. Labarthe (1995)
Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991.Hypertension, 25 3
N. Hollenberg (2003)
Literature alertCurrent Hypertension Reports, 5
M. Velussi, E. Brocco, F. Frigato, M. Zolli, B. Muollo, M. Maioli, A. Carraro, G. Tonolo, P. Fresu, A. Cernigoi, P. Fioretto, R. Nosadini (1996)
Effects of Cilazapril and Amlodipine on Kidney Function in Hypertensive NIDDM PatientsDiabetes, 45
A. Noronha-Dutra, E. Steen-Dutra, N. Woolf (1991)
An antioxidant role for calcium antagonists in the prevention of adrenaline mediated myocardial and endothelial damage.British Heart Journal, 65
R. Sanchez, M. Ayala, H. Baglivo, C. Velazquez, G. Burlando, O. Kohlmann, J. Jiménez, P. Jaramillo, A. Brandão, G. Valdés, L. Alcocer, M. Bendersky, A. Ramirez, A. Zanchetti (2009)
Latin American guidelines on hypertension. Latin American Expert Group.Journal of hypertension, 27 5
P. Leeuw, L. Ruilope, C. Palmer, Morris Brown, A. Castaigne, G. Mancia, T. Rosenthal, G. Wagener (2004)
Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial.Archives of internal medicine, 164 22
C. Pepine, E. Handberg, R. Cooper-DeHoff, R. Marks, P. Kowey, F. Messerli, G. Mancia, J. Cangiano, D. García-Barreto, M. Keltai, S. Erdine, Heather Bristol, Ms Kolb, G. Bakris, Jerome Cohen, W. Parmley (2003)
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.JAMA, 290 21
M. Verhaar, M. Honing, T. Dam, M. Zwart, Hendrik Koomans, J. Kastelein, T. Rabelink (1999)
Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids.Cardiovascular research, 42 3
D. Lloyd‐Jones, R. Adams, M. Carnethon, G. Simone, T. Ferguson, K. Flegal, E. Ford, K. Furie, A. Go, K. Greenlund, Nancy Haase, S. Hailpern, Michael Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M. McDermott, J. Meigs, D. Mozaffarian, G. Nichol, Christopher O'Donnell, V. Roger, W. Rosamond, R. Sacco, P. Sorlie, R. Stafford, J. Steinberger, T. Thom, S. Wasserthiel-Smoller, N. Wong, J. Wylie-Rosett, Yuling Hong (2009)
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation, 119 3
B. Pitt, R. Byington, C. Furberg, D. Hunninghake, Gabriele Mancini, Michael Miller, W. Riley (2000)
Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical EventsCirculation: Journal of the American Heart Association, 102
W. Elliott, P. Meyer (2007)
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysisThe Lancet, 369
E. Kuschnir, M. Bendersky, J. Resk, Maria Pañart, L. Guzman, Y. Plotquin, G. Grassi, G. Mancia, G. Wagener (2004)
Effects of the Combination of Low-Dose Nifedipine GITS 20 mg and Losartan 50 mg in Patients with Mild to Moderate HypertensionJournal of Cardiovascular Pharmacology, 43
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.JAMA, 289 19
F. Messerli, G. Noll, L. Lindholm, H. Haller, L. Ruilope, M. Volpe (2006)
The Role of Dihydropyridine Calcium Channel Blockers in the Treatment of Hypertension and Cardiovascular Disease - An UpdateEuropean Cardiology Review, 2
W. Frishman, J. Hainer, J. Sugg (2006)
A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT).American journal of hypertension, 19 4
B. Diaz, J. Carrillo, H. Hernández (2008)
Una versión minimalista sobre el tratamiento de la hipertensión arterial. Esquemas de tratamiento antihipertensor, 19
F. Messerli, S. Oparil, Zhanbin Feng (2000)
Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension.The American journal of cardiology, 86 11
G. Viberti, N. Wheeldon (2002)
Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent EffectCirculation: Journal of the American Heart Association, 106
A. Arredondo, Alexis Zúñiga (2006)
Epidemiologic changes and economic burden of hypertension in Latin America: evidence from Mexico.American journal of hypertension, 19 6
R.A. Sanchez, M. Ayala, H. Baglivo (2009)
Latin American guidelines on hypertensionJ Hypertens, 27
Deepak Bhatt, P. Steg, E. Ohman, A. Hirsch, Y. Ikeda, J. Mas, S. Goto, C. Liau, A. Richard, J. Röther, P. Wilson (2006)
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.JAMA, 295 2
J. Lubsen, G. Wagener, B. Kirwan, S. Brouwer, P. Poole‐Wilson (2005)
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trialJournal of Hypertension, 23
S. Chrysant, M. Melino, Sulekha Karki, James Lee, R. Heyrman (2008)
The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.Clinical therapeutics, 30 4
T. Lüscher, M. Pieper, M. Tendera, M. Vrolix, W. Rutsch, F. Branden, R. Gil, K. Bischoff, M. Haude, D. Fischer, T. Meinertz, T. Münzel (2009)
A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study†European Heart Journal, 30
N. Hasebe, K. Kikuchi (2005)
Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) StudyJournal of Hypertension, 23
J. Staessen, R. Fagard, L. Thijs, H. Celis, G. Arabidze, W. Birkenhäger, C. Bulpitt, P. Leeuw, C. Dollery, A. Fletcher, F. Forette, G. Leonetti, C. Nachev, E. Brien, J. Rosenfeld, J. Rodicio, J. Tuomilehto, A. Zanchetti (1997)
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertensionThe Lancet, 350
J. Whitworth (2003)
2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertensionJournal of Hypertension, 21
Encore Investigators (2003)
Effect of Nifedipine and Cerivastatin on Coronary Endothelial Function in Patients With Coronary Artery Disease: The ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function)Circulation: Journal of the American Heart Association, 107
N. Borhani, M. Mercuri, P. Borhani, V. Buckalew, M. Canossa-Terris, A. Carr, T. Kappagoda, M. Rocco, H. Schnaper, J. Sowers, M. Bond (1996)
Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial.JAMA, 276 10
P. Lichtlen, W. Rafflenbeul, H. Hecker, S. Jost, P. Hugenholtz, J. Deckers (1990)
Retardation of angiographic progression of coronary artery disease by nifedipineThe Lancet, 335
I. Saito, T. Saruta (2006)
Controlled Release Nifedipine and Valsartan Combination Therapy in Patients with Essential Hypertension: The Adalat CR and Valsartan Cost-Effectiveness Combination (ADVANCE-Combi) StudyHypertension Research, 29
Y. Ostchega, S. Yoon, Jeffery Hughes, Tatiana Louis (2008)
Hypertension awareness, treatment, and control--continued disparities in adults: United States, 2005-2006.NCHS data brief, 3
T. Philipp, T. Smith, R. Glazer, M. Wernsing, J. Yen, James Jin, H. Schneider, R. Pospiech (2007)
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.Clinical therapeutics, 29 4
P. Poole-Wilson, J. Lubsen, B. Kirwan, F. Dalen, G. Wagener, N. Danchin, H. Just, K. Fox, S. Pocock, Tim Clayton, M. Motro, John Parker, M. Bourassa, Anthony Dart, P. Hildebrandt, A. Hjalmarson, A. Johannes, Kragten, G. Molhoek, J. Otterstad, R. Seabra‐Gomes, J. Soler‐Soler, S. Weber (2004)
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trialThe Lancet, 364
A. Zanchetti, E. Rosei, C. Palù, G. Leonetti, B. Magnani, A. Pessina (1998)
The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long‐term randomized treatment with either verapamil or chlorthalidone on carotid intima‐media thicknessJournal of Hypertension, 16
C. Murray, Alan Lopez (1997)
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease StudyThe Lancet, 349
P. Ruggenenti, A. Fassi, Anelja Ilieva, Simona Bruno, I. Iliev, Varusca Brusegan, N. Rubis, Giulia Gherardi, Federica Arnoldi, M. Ganeva, B. Ene-Iordache, F. Gaspari, A. Perna, A. Bossi, R. Trevisan, A. Dodesini, G. Remuzzi (2004)
Preventing microalbuminuria in type 2 diabetes.The New England journal of medicine, 351 19
Cardiovascular disease (CVD) is a continuum that begins with the presence of several risk factors for CVD, including smoking, hypertension, obesity, diabetes mellitus, and high levels of cholesterol, and if unaddressed can result in premature death, ischemic heart disease, stroke, congestive heart failure, and end-stage renal disease. Hypertension is associated with a significant increase in cardiovascular (CV) morbidity and mortality, raising the risk of stroke, myocardial infarction, heart failure, kidney disease, and peripheral arterial disease. In Latin America, the prevalence of hypertension and other CV risk factors has become similar to that seen in more developed countries, increasing the proportion of the population at high risk for CVD and congestive heart failure; however, it is hypertension that is a key driving force behind CV risk in Latin America. Despite the existence of a wide range of antihypertensive agents, BP control and reductions in CV risk remain poor in Latin America and in Hispanics living in the US. Ethnic differences in treatment rates and disease awareness have been well documented. Studies have shown that calcium channel blockers (CCBs; calcium channel antagonists) are at least as effective in reducing BP and improving the CV risk profile as other classes of antihypertensive agents when administered as monotherapy. CCBs have also been shown to be effective when administered as part of combination therapy in both low- and high-risk hypertensive patients, suggesting that CCBs can easily be combined with other antihypertensive classes in order to achieve BP control and CV risk reduction. In patients with hypertension, coronary artery disease, and high cholesterol, CCBs have been associated with beneficial effects on a range of other aspects of the CV continuum, including the vasculature, coronary calcification, and progression of atherosclerosis. CCBs have also been shown to preserve renal function. Unlike diuretics and β-adrenoreceptor antagonists, CCBs are metabolically neutral, inducing minimal changes in serum lipids and decreasing the incidence of new-onset diabetes compared with other antihypertensive agents. CCBs are well tolerated when administered as monotherapy or combination therapy, with long-acting formulations minimizing adverse events even further compared with short-acting formulations. These characteristics make CCBs an attractive option for the treatment of hypertension and CV risk in Latin America, which remain significant health issues in this region.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 17, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.